Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 60760-645 by St. Mary's Medical Park Pharmacy, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
645 - Losartan 645 30
NDC 60760-645-30 is a tablets medication called Losartan that includes potassium - manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd, China. The tablets contain 50mg Potassium and the package size is 30 tablets. Additionally, it includes LOT# and EXP date for product identification. The medication is for prescription use only, and should be stored at temperatures between 15°C-30°C (59°F-86°F). If any further details on the medication are required, please refer to Use as Directed at the given website.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
The text provides information about a study where the drug Atenolol was compared with Losartan Potassium in patients. The primary endpoint was measured as the percentage of patients at a specific risk level, and the study was conducted over a period of 66 months. The risk reduction was found to be 13% with a significance level of p=0.021.*
Figure 2 - spl image3 figure2
This text seems to be presenting data about a comparison between two drugs: Atenolol and Losartan Potassium. It suggests that Losartan Potassium may have an adjusted risk reduction of 25% compared to Atenolol, with statistical significance (p=0.001). The text also appears to show percentages of patients with fatal/non-fatal strokes over the course of some study months, ranging from 6 to 66. However, without more context or clear headings, it is difficult to interpret the information fully.*
Figure 3 - spl image4 figure3
The text describes primary composite stroke events in demographic subgroups for a clinical trial comparing the effectiveness of Losartan Potassium and Atenolol. The trial studied the effects on patients with different age groups, gender, race, presence/absence of ischemic heart disease, diabetes, history of cardiovascular diseases. The text also mentions the hazard ratio and adjusted baseline risk of patients.*
Figure 4 - spl image5 figure4
This is a graph showing the percentage of patients experiencing an event over time. The graph compares the effects of Losartan Potassium versus a placebo, with Losartan Potassium showing a risk reduction of 16.1% and a p-value of 0.022. The x-axis shows the duration of the study in months.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.